About Baxter International Inc.
https://www.baxter.comBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
CEO
David Brent Shafer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-07-01 | Forward | 1841:1000 |
| 2001-05-31 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 539
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Evercore ISI Group
Outperform
Barclays
Overweight
Wells Fargo
Equal Weight
Citigroup
Neutral
UBS
Neutral
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:77.83M
Value:$1.54B
BLACKROCK INC.
Shares:63.03M
Value:$1.25B
VANGUARD GROUP INC
Shares:62.53M
Value:$1.24B
Summary
Showing Top 3 of 1,229
About Baxter International Inc.
https://www.baxter.comBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.83B ▲ | $998M ▲ | $-46M ▼ | -1.62% ▼ | $-0.09 ▼ | $416M ▼ |
| Q2-2025 | $2.81B ▲ | $939M ▲ | $91M ▼ | 3.24% ▼ | $0.18 ▼ | $462M ▲ |
| Q1-2025 | $2.63B ▼ | $803M ▼ | $126M ▲ | 4.8% ▲ | $0.25 ▲ | $325M ▲ |
| Q4-2024 | $2.75B ▲ | $1.39B ▲ | $-512M ▼ | -18.6% ▼ | $-1 ▼ | $-176M ▼ |
| Q3-2024 | $2.7B | $878M | $140M | 5.19% | $0.27 | $299M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.73B ▲ | $21.07B ▲ | $13.85B ▲ | $7.24B ▼ |
| Q2-2025 | $1.69B ▼ | $21.05B ▼ | $13.75B ▼ | $7.32B ▲ |
| Q1-2025 | $2.29B ▲ | $21.3B ▼ | $14.25B ▼ | $7.08B ▲ |
| Q4-2024 | $1.76B ▲ | $25.78B ▼ | $18.76B ▲ | $6.96B ▼ |
| Q3-2024 | $1.42B | $26.68B | $18.73B | $7.87B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-51M ▼ | $237M ▲ | $-111M ▲ | $-81M ▲ | $40M ▲ | $126M ▲ |
| Q2-2025 | $122M ▲ | $217M ▲ | $-115M ▼ | $-762M ▲ | $-608M ▼ | $68M ▲ |
| Q1-2025 | $64M ▲ | $-193M ▼ | $3.27B ▲ | $-3.23B ▼ | $-118M ▼ | $-315M ▼ |
| Q4-2024 | $-488M ▼ | $488M ▲ | $-205M ▼ | $141M ▲ | $334M ▲ | $351M ▲ |
| Q3-2024 | $434M | $253M | $-164M | $-146M | $-16M | $229M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Healthcare Systems and Technologies | $780.00M ▲ | $700.00M ▼ | $770.00M ▲ | $770.00M ▲ |
 Medical Products And Therapies | $1.31Bn ▲ | $1.26Bn ▼ | $1.32Bn ▲ | $1.33Bn ▲ |
 Pharmaceuticals | $640.00M ▲ | $580.00M ▼ | $610.00M ▲ | $630.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 EMEA | $0 ▲ | $350.00M ▲ | $340.00M ▼ | $300.00M ▼ |
 UNITED STATES | $890.00M ▲ | $1.54Bn ▲ | $1.54Bn ▲ | $1.49Bn ▼ |
 Western Europe Canada Japan Australia and New Zealand | $260.00M ▲ | $940.00M ▲ | $930.00M ▼ | $840.00M ▼ |
CEO
David Brent Shafer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-07-01 | Forward | 1841:1000 |
| 2001-05-31 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 539
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Evercore ISI Group
Outperform
Barclays
Overweight
Wells Fargo
Equal Weight
Citigroup
Neutral
UBS
Neutral
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:77.83M
Value:$1.54B
BLACKROCK INC.
Shares:63.03M
Value:$1.25B
VANGUARD GROUP INC
Shares:62.53M
Value:$1.24B
Summary
Showing Top 3 of 1,229